GRFS Stock Analysis: Buy, Sell, or Hold?
GRFS - Grifois, S.A.
$7.86
-0.01 (-0.13%)
▼
5d:
+1.42%
30d:
+9.78%
90d:
-4.5%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 03, 2026
0d
Get Alerted When GRFS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: GRFS shows positive signals but monitor for confirmation. Market pricing in 2.5% decline. Moderate conviction.
💡 BUY OPPORTUNITY: GRFS shows positive signals but monitor for confirmation. Market pricing in 2.5% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$16.40
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$10.18
22.8% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 5.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GRFS is currently trading at $7.86, which is considered extended relative to its 30-day fair value range of $7.10 to $7.74. The stock's valuation (Forward PE: 5.5) is in line with its historical norms (5.9). Remarkably, the market is currently pricing in an annual earnings decline of 2.5% over the next few years. This pessimistic expectation contrasts with the company's recent 43.5% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, GRFS is in a downtrend. Immediate support is located at $7.52, while resistance sits at $8.37.
Market Sentiment: GRFS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $10.87 (+38.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GRFS is in a downtrend. Immediate support is located at $7.52, while resistance sits at $8.37.
Market Sentiment: GRFS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $10.87 (+38.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$7.10 -
$7.74
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 38.1% below Wall St target ($10.87)
Trading Range Analysis
30-Day Trading Range
$7.10 -
$7.74
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$7.52
Resistance Level
$8.37
Current Trend
Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
5.52
Wall Street Target
$10.87
(+38.1%)
Revenue Growth (YoY)
-0.9%
Earnings Growth (YoY)
43.5%
Profit Margin
6.1%
Valuation Discount vs History
-2.5% cheaper
PE vs Historical
5.5 vs 5.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.5%
(market-implied from PE analysis)
1-Year Target
$7.67
(-3%)
2-Year Target
$7.48
(-5%)
3-Year Target
$7.29
(-7%)
3-Yr Target (if PE normalizes)
(PE: 6→6)
$7.80
(-1%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.7, Growth: 28.4%)
$62.57
(+695%)
Base:
(SPY PE: 5.5, Growth: 28.4%)
$16.65
(+112%)
Bear:
(PE: 4.7, Growth: 28.4%)
$14.15
(+80%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (11x PE), but valuation improves significantly next year (6x PE) as earnings recover.
Trailing PE: 10.79 | Current EPS (TTM): $0.76
Bull Case
$16.94
(+115%)
Analyst growth 87.8%, PE expands to 11.9
Base Case
$15.40
(+96%)
Market implied 87.8%, PE stable at 10.8
Bear Case
$5.58
(-29%)
Severe decline -20.0%, PE contracts to 9.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 5.5 to 5.9
Stabilization Target:
$8.42
(+7.0%)
PE Expansion Potential:
+7.0%
Share & Embed Analysis
Last updated: August 03, 2026 4:31 PM ET
Data refreshes hourly during market hours. Next update: 5:31 PM
Data refreshes hourly during market hours. Next update: 5:31 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GRFS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1277 | 49 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$157 | 54 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$357 | 56 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$234 | 55 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$270 | 52 HOLD |
